StefanH.FaderlMD

Oncology • Palo Alto, CA

Hematologic Oncology

Chief, Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center

Join to view full profile

Dr. Faderl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Faderl's full profile

Already have an account?

Office
3170 Porter Drive
Palo Alto, CA 94304

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Steward Carney HospitalResidency, Internal Medicine, 1993 - 1996
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1990

Certifications & Licensure

TX State Medical License 1999 - 2025
NJ State Medical License 2013 - 2017
American Board of Internal Medicine Internal Medicine

Clinical Trials

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Start of enrollment: 2001 Sep 06
Completed
Phase 1
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Start of enrollment: 2003 Jun 23
Completed
Phase 2
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) Start of enrollment: 2003 Dec 01
Completed
Phase 2
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2004 May 01
Terminated
Phase 1
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients Start of enrollment: 2006 Mar 01
Completed
Phase 1, Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 2007 Jul 11
Recruiting
Phase 2
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Nov 01
Withdrawn
Phase 1
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Start of enrollment: 2011 Jul 01
Completed
Phase 1
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2011 Nov 16
Completed
Phase 2
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Selinexor (KPT-330) in Older Patients With Relapsed AML Start of enrollment: 2014 Mar 01
Completed
Phase 2
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

10 citations
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: pos...
Jorge E Cortes, Tara L Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E Lancet
Journal of Hematology & Oncology. 2022-10-26
8 citations
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl
Journal of Hematology & Oncology. 2021-07-13
81 citations
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...
Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie
The Lancet. Haematology. 2021-07-01

Abstracts/Posters

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

John Theurer Cancer Center (JTCC) Researchers to Present 52 Abstracts Across Hematological Malignancies at the 2020 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 4th, 2020